Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 422

1.

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T.

Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22.

PMID:
21784052
2.

The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.

Xiang L, Li M, Liu Y, Cen J, Chen Z, Zhen X, Xie X, Cao X, Gu W.

Ann Hematol. 2013 Aug;92(8):1063-9. doi: 10.1007/s00277-013-1729-x. Epub 2013 Mar 21.

PMID:
23515710
3.

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.

Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC, Bartel F.

Cancer Res. 2010 Dec 1;70(23):9641-9. doi: 10.1158/0008-5472.CAN-10-0527. Epub 2010 Nov 16.

4.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ.

Blood. 2005 Dec 1;106(12):3747-54. Epub 2005 Aug 18.

5.

miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death.

Bryant A, Palma CA, Jayaswal V, Yang YW, Lutherborrow M, Ma DD.

Mol Cancer. 2012 Feb 20;11:8. doi: 10.1186/1476-4598-11-8.

6.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Russ AC, Sander S, Lück SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.

Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888. Epub 2011 Aug 31.

7.

miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia.

Pigazzi M, Manara E, Baron E, Basso G.

Cancer Res. 2009 Mar 15;69(6):2471-8. doi: 10.1158/0008-5472.CAN-08-3404. Epub 2009 Mar 3.

9.

Differential expression of specific microRNA and their targets in acute myeloid leukemia.

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A, Bica MG, Cascio L, Floridia PM, Mineo AM, Russo M, Fabbiano F, Santoro A.

Am J Hematol. 2010 May;85(5):331-9. doi: 10.1002/ajh.21667.

10.

Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature.

Krstovski N, Tosic N, Janic D, Dokmanovic L, Kuzmanovic M, Spasovski V, Pavlovic S.

Med Oncol. 2010 Sep;27(3):640-5. doi: 10.1007/s12032-009-9261-5. Epub 2009 Jun 26. Review.

PMID:
19557552
11.

MicroRNA29a regulates the expression of the nuclear oncogene Ski.

Teichler S, Illmer T, Roemhild J, Ovcharenko D, Stiewe T, Neubauer A.

Blood. 2011 Aug 18;118(7):1899-902. doi: 10.1182/blood-2010-09-306258. Epub 2011 Jun 17.

12.

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50. doi: 10.1073/pnas.0800135105. Epub 2008 Feb 28.

13.

Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.

Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F.

Mol Cancer Res. 2008 Dec;6(12):1830-40. doi: 10.1158/1541-7786.MCR-08-0167.

14.

Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.

Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, Downing JR.

Leukemia. 2007 Sep;21(9):2000-9. Epub 2007 Jun 28.

PMID:
17597811
15.
16.

A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.

Illmer T, Schaich M, Oelschlägel U, Nowak R, Renner U, Ziegs B, Subat S, Neubauer A, Ehninger G.

Leuk Res. 1999 Jul;23(7):653-63.

PMID:
10400187
17.
18.

Stromal-mediated down-regulation of CD13 in bone marrow cells originating from acute myeloid leukemia patients.

Dybkaer K, Olesen G, Pedersen FS, Kristensen JS.

Eur J Haematol. 2001 Mar;66(3):168-77.

PMID:
11350485
19.

A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.

van Stijn A, Kok A, van der Pol MA, Feller N, Roemen GM, Westra AH, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2003 Apr;17(4):780-6.

PMID:
12682637

Supplemental Content

Support Center